1361224-53-4 Usage
Description
AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor, which can significantly enhance the dissociation of the GK-GKRP complex and promote GK translocation in-vivo. It is a promising drug candidate for the treatment of type II diabetes, as it effectively reduces blood glucose levels in rodent models of diabetes without impacting euglycemic animals, thus offering a potential solution with a reduced risk of hypoglycemia.
Uses
Used in Pharmaceutical Industry:
AMG-3969 is used as an antidiabetic agent for the treatment of type II diabetes. It functions by disrupting the GK-GKRP interaction, which leads to an increase in GK translocation and, consequently, a reduction in blood glucose levels. This mechanism of action presents a potential advantage over traditional diabetes treatments, as it may lower the risk of hypoglycemic events.
Additionally, given its specific mode of action, AMG-3969 could be used as a research tool in the study of GK-GKRP interactions and their role in glucose homeostasis, potentially leading to the development of other novel therapeutics for diabetes management.
References
Lloyd, David J., et al. "Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors." Nature 504.7480(2013):437-40.
Bourbeau, M. P., et al. "Nonracemic synthesis of GK-GKRP disruptor AMG-3969. " Synfacts 79.8(2014):3684.
http://www.metonchem.com/products/amg-3969-cas1361224-53-4/
Check Digit Verification of cas no
The CAS Registry Mumber 1361224-53-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,2,2 and 4 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1361224-53:
(9*1)+(8*3)+(7*6)+(6*1)+(5*2)+(4*2)+(3*4)+(2*5)+(1*3)=124
124 % 10 = 4
So 1361224-53-4 is a valid CAS Registry Number.
1361224-53-4Relevant articles and documents
Nonracemic synthesis of GK-GKRP disruptor AMG-3969
Bourbeau, Matthew P.,Ashton, Kate S.,Yan, Jie,St. Jean, David J.
, p. 3684 - 3687 (2014/05/06)
A nonracemic synthesis of the glucokinase-glucokinase regulatory protein disruptor AMG-3969 (5) is reported. Key features of the synthetic approach are an asymmetric synthesis of the 2-alkynyl piperazine core via a base-promoted isomerization and a revised approach to the synthesis of the aminopyridinesulfonamide with an improved safety profile.
SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN
-
, (2013/08/28)
The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
-
, (2012/03/26)
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
